Patients with HER2‐positive breast cancer commonly respond favorably to neoadjuvant chemotherapy with the HER2‐targeted agent trastuzumab, leading to improved disease‐free survival and overall survival.38, 39. The gene discussed is ERBB2; the disease is breast carcinoma.